ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.779,58
0,53%
S&P 500
5.214,08
0,51%
Dow Jones
39.387,76
0,00%
Euro vs US Dollar
1,07775
-0,04%
Bitcoin
63.020,00
-0,05%
Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. AMEX
  6. AgeX Therapeutics Inc (AGE)

  7. AgeX Therapeutics Inc (AGE) News

AGE

AgeX Therapeutics (AGE)

AgeX Therapeutics Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:AMEX:AGE
DatumZeitQuelleÜberschriftSymbolFirma
22/03/202422h27GlobeNewswire Inc.AgeX Therapeutics Reports Fourth Quarter and Annual 2023 Financial ResultsAMEX:AGEAgeX Therapeutics Inc
07/03/202422h49Edgar (US Regulatory)Form 425 - Prospectuses and communications, business combinationsAMEX:AGEAgeX Therapeutics Inc
07/03/202422h47Edgar (US Regulatory)Form 8-K - Current reportAMEX:AGEAgeX Therapeutics Inc
07/03/202413h47Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]AMEX:AGEAgeX Therapeutics Inc
14/02/202422h01Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]AMEX:AGEAgeX Therapeutics Inc
14/02/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessAMEX:AGEAgeX Therapeutics Inc
06/02/202422h05Edgar (US Regulatory)Form 8-K - Current reportAMEX:AGEAgeX Therapeutics Inc
05/02/202413h19Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]AMEX:AGEAgeX Therapeutics Inc
19/01/202422h05Edgar (US Regulatory)Form 8-K - Current reportAMEX:AGEAgeX Therapeutics Inc
18/01/202423h29Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesAMEX:AGEAgeX Therapeutics Inc
17/01/202422h19Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]AMEX:AGEAgeX Therapeutics Inc
16/01/202415h11Edgar (US Regulatory)Form S-4/A - Registration of securities, business combinations: [Amend]AMEX:AGEAgeX Therapeutics Inc
11/01/202422h05Edgar (US Regulatory)Form 8-K - Current reportAMEX:AGEAgeX Therapeutics Inc
09/01/202422h16Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]AMEX:AGEAgeX Therapeutics Inc
05/01/202422h05Edgar (US Regulatory)Form 8-K - Current reportAMEX:AGEAgeX Therapeutics Inc
28/12/202322h02Edgar (US Regulatory)Form 8-K - Current reportAMEX:AGEAgeX Therapeutics Inc
18/12/202322h25Edgar (US Regulatory)Form 8-K - Current reportAMEX:AGEAgeX Therapeutics Inc
13/12/202323h11Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]AMEX:AGEAgeX Therapeutics Inc
08/12/202322h05Edgar (US Regulatory)Form 8-K - Current reportAMEX:AGEAgeX Therapeutics Inc
01/12/202322h05Edgar (US Regulatory)Form 8-K - Current reportAMEX:AGEAgeX Therapeutics Inc
17/11/202322h05Edgar (US Regulatory)Form 8-K - Current reportAMEX:AGEAgeX Therapeutics Inc
16/11/202322h01Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]AMEX:AGEAgeX Therapeutics Inc
15/11/202315h38Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsAMEX:AGEAgeX Therapeutics Inc
14/11/202322h25Edgar (US Regulatory)Form 8-K - Current reportAMEX:AGEAgeX Therapeutics Inc
14/11/202322h05Business WireAgeX Therapeutics Reports Third Quarter 2023 Financial ResultsAMEX:AGEAgeX Therapeutics Inc
07/11/202322h06Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialAMEX:AGEAgeX Therapeutics Inc
07/11/202322h05Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsAMEX:AGEAgeX Therapeutics Inc
06/11/202322h05Edgar (US Regulatory)Form 8-K - Current reportAMEX:AGEAgeX Therapeutics Inc
01/11/202321h28Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]AMEX:AGEAgeX Therapeutics Inc
06/10/202322h05Edgar (US Regulatory)Form 8-K - Current reportAMEX:AGEAgeX Therapeutics Inc
 Showing the most relevant articles for your search:AMEX:AGE

Kürzlich von Ihnen besucht

TG
BAYN
Bayer
TG
RHM
Rheinmetall
NASDAQ
QQQ
Invesco QQQ Trust Series 1
TG
D7G
Nel ASA
USOTC
RHHBY
Roche (QX)
USOTC
DTEGY
Deutsche Telekom (QX)
NYSE
NKE
Nike
CCOM
US30
US 30
NYSE
MRK
Merck
NASDAQ
GOOGL
Alphabet
DBI
DAX
DAX
NYSE
XOM
Exxon Mobil
NYSE
KO
Coca Cola
AMEX
XLF
Financial Select Sector
NYSE
DIS
Walt Disney
NYSE
JPM
JP Morgan Chase
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten